MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Metrics to compare | 0ACH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0ACHPeersSector | |
---|---|---|---|---|
P/E Ratio | −49.3x | 14.8x | −0.7x | |
PEG Ratio | −1.82 | 0.02 | 0.00 | |
Price/Book | −55.5x | 2.3x | 2.6x | |
Price / LTM Sales | 32.8x | 3.4x | 3.4x | |
Upside (Analyst Target) | - | 115.5% | 37.9% | |
Fair Value Upside | Unlock | 13.4% | 5.2% | Unlock |